• TEXT SIZE

What Is ENBREL?

ENBREL is a prescription medicine that can be self-injected. It is used to treat five long-term inflammatory diseases: moderate to severe rheumatoid arthritis (RA), adult chronic moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy, psoriatic arthritis, moderate to severe juvenile idiopathic arthritis (JIA), and ankylosing spondylitis (AS).


ENBREL is grouped within a class of medications called biologic response modifiers, or biologics. By working on the immune system, biologics block proteins that contribute to the disease process. Because ENBREL suppresses the immune system, patients are at a greater risk for getting serious infections.

The science behind ENBREL

Tumor necrosis factor (TNF) is a substance made by your body's immune system. People with inflammatory diseases such as rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis have too much TNF in their bodies. ENBREL reduces levels of the active form of TNF.

The clinical history of ENBREL

  • ENBREL was the first biologic approved for moderate to severe rheumatoid arthritis
  • ENBREL has an established safety profile
  • ENBREL has over 10 years of continuous safety data in patients with moderate to severe rheumatoid arthritis

How ENBREL is taken

Taking ENBREL can be simple. ENBREL is injected (by you or a trained caregiver) just under the skin in the comfort of your own home. ENBREL is available in multiple injection options. And with the design of the Enbrel® (etanercept) SureClick® autoinjector, you'll never even have to see the needle. Schedule a training session with your doctor's office to learn the proper way to self-inject.

Click here to learn more about injecting ENBREL and to view step-by-step injection videos.

Injection site reactions such as redness, rash, swelling, itching, or bruising may occur. These symptoms usually go away within 3 to 5 days. If you experience these reactions and they don't go away or get worse, call your doctor.

If you have questions about injecting ENBREL, you can speak to a registered nurse at no cost to you. Just call 1-888-4ENBREL (1-888-436-2735) from 8 AM to 11 PM Eastern time, 7 days a week. This is just one of the many benefits of our ENBREL Support™ program.

Please see Prescribing Information, Important Safety Information, and Medication Guide for complete details about ENBREL.

Learn more about ENBREL Support™

Prescription ENBREL is taken by injection.

IMPORTANT SAFETY INFORMATION
Indications

Moderate to Severe Rheumatoid Arthritis (RA)
ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with moderate to severe rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.

Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA)
ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older.

Psoriatic Arthritis
ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

Ankylosing Spondylitis (AS)
ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

Moderate to Severe Plaque Psoriasis
ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Supportive data
Moderate to Severe Rheumatoid Arthritis (RA)
  • In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.
Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA)
  • In a clinical study, ENBREL was shown to be effective in about 3 out of 4 children with JIA who used it at 3 months. ENBREL has been shown to begin working in as few as 2 to 4 weeks.
Psoriatic Arthritis
  • ENBREL was shown to be effective in about 50% of patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.
Ankylosing Spondylitis (AS)
  • ENBREL was shown to be effective in about 3 out of 5 adults at 6 months. Clinical responses were seen at 2 weeks in 46% of patients, with 59% of patients receiving benefit within 8 weeks.
Moderate to Severe Plaque Psoriasis
  • In medical studies, nearly half of patients saw 75% skin clearance in 3 months. Overall, 3 out of 4 patients saw 50% skin clearance in 3 months.
Want more information?

Sign up today to receive information about ENBREL.

ENROLL NOW
Learn more about the ENBREL Support program.